BRAF and melanoma: Data from a large case collection of melanoma patients with rare BRAF mutants showed in a subpopulation of 38 non-V600 BRAF-mutated patients an ORR of 18% for MAPK inhibition with none of 15 patients responding to BRAFi, two of five patients (40%) responding to MEKi, and five of 18 patients (28%) responding to a BRAFi/MEKi combination [13••].